Focused On-demand Libraries - Receptor.AI Collaboration


Explore the Potential with AI-Driven Innovation

Our detailed focused library is generated on demand with advanced virtual screening and parameter assessment technology powered by the Receptor.AI drug discovery platform. This method surpasses traditional approaches, delivering compounds of better quality with enhanced activity, selectivity, and safety.


The compounds are cherry-picked from the vast virtual chemical space of over 60B molecules. The synthesis and delivery of compounds is facilitated by Reaxense.


The library includes a list of the most promising modulators annotated with 38 ADME-Tox and 32 physicochemical and drug-likeness parameters. Also, each compound is presented with its optimal docking poses, affinity scores, and activity scores, providing a comprehensive overview.


We employ our advanced, specialised process to create targeted libraries.


 

Fig. 1. The screening workflow of Receptor.AI

Utilising molecular simulations, our approach thoroughly examines a wide array of proteins, tracking their conformational changes individually and within complexes. Ensemble virtual screening enables us to address conformational flexibility, revealing essential binding sites at functional regions and allosteric locations. Our rigorous analysis guarantees that no potential mechanism of action is overlooked, aiming to uncover new therapeutic targets and lead compounds across diverse biological functions.


Our library stands out due to several important features:


  • The Receptor.AI platform compiles comprehensive data on the target protein, encompassing previous experiments, literature, known ligands, structural details, and more, leading to a higher chance of selecting the most relevant compounds.

  • Advanced molecular simulations on the platform help pinpoint potential binding sites, making the compounds in our focused library ideal for finding allosteric inhibitors and targeting cryptic pockets.

  • Receptor.AI boasts over 50 tailor-made AI models, rigorously tested and proven in various drug discovery projects and research initiatives. They are crafted for efficacy, dependability, and precision, all of which are key in creating our focused libraries.

  • Beyond creating focused libraries, Receptor.AI offers comprehensive services and complete solutions throughout the preclinical drug discovery phase. Our success-based pricing model minimises risk and maximises the mutual benefits of the project's success.


PARTNER
Receptor.AI
 
UPACC
A0AVF1

UPID:
IFT56_HUMAN

ALTERNATIVE NAMES:
Tetratricopeptide repeat protein 26

ALTERNATIVE UPACC:
A0AVF1; A4D1S3; B7Z5M0; C9J2N7; F8W724; Q9H9S8; Q9NTC0

BACKGROUND:
The Intraflagellar transport protein 56, known alternatively as Tetratricopeptide repeat protein 26, is a key component of the IFT complex B, required for protein transport in the motile cilium. It plays a critical role in the efficient coupling between the accumulation of GLI2 and GLI3 at the ciliary tips and their dissociation from SUFU, maintaining the integrity of the IFT complex B and proper localization of its components.

THERAPEUTIC SIGNIFICANCE:
Given its crucial role in Biliary, renal, neurologic, and skeletal syndrome, a disease marked by severe multisystemic manifestations, the study of Intraflagellar transport protein 56 holds promise for the development of novel therapeutic interventions. Its significance in disease pathology makes it a prime target for drug discovery efforts aimed at mitigating the syndrome's diverse clinical features.

Looking for more information on this library or underlying technology? Fill out the form below and we will be in touch with all the details you need.